The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Clovis Oncology; Dendreon; Foundation Medicine; Gilead Sciences; Janssen Scientific Affairs; Myovant Sciences; Procept Biorobotics; Progenics; Seagen
 
Se Kim
No Relationships to Disclose
 
Andrew Wentland
No Relationships to Disclose
 
Mu-Han Lin
No Relationships to Disclose
 
Payal Kapur
No Relationships to Disclose
 
Elizabeth Wulff-Burchfield
Stock and Other Ownership Interests - Immunomedics (I); Nektar (I)
Consulting or Advisory Role - Aptitude Health; Astellas Scientific and Medical Affairs Inc; AVEO; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Targeted Oncology
Research Funding - Acerta Pharma/AstraZeneca (Inst); Pfizer
Patents, Royalties, Other Intellectual Property - Methods of use patent application has been submitted for the pharmaceutical product Osanetant, owned by Acer Therapeutics.
 
Daniel Shevrin
Consulting or Advisory Role - Astellas Pharma
 
Tami Gurley
No Relationships to Disclose
 
John Lin
No Relationships to Disclose
 
Lynne Wagner
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene
 
Rana McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
James Brugarolas
Honoraria - Regeneron
Consulting or Advisory Role - Exelixis; Johnson & Johnson; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - U.S. Application Number: 17/153,128 “PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha” (Inst); U.S. Application Number: 17/206,895 “BIOMARKERS OF RESPONSE TO HIF-2alpha INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF” (Inst); U.S. Patent: US 11,576,889 B2 "METHODS OF IDENTIFYING AND TREATING PATIENTS WITH HIF-2 INHIBITOR RESISTANCE" (Inst)
 
Qian Qin
Honoraria - MashupMedia; MJH Life Sciences
Consulting or Advisory Role - Exelixis
 
Tyler Gunter
Employment - University of Oklahoma Health Sciences Center
Research Funding - Mevion Medical Systems (Inst)
 
Christos Kyriakopoulos
Employment - Epic Systems (I)
Stock and Other Ownership Interests - Biogen; Epic Systems (I)
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca; Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); ESSA; Gilead Sciences; Madison Vaccines, Inc. (Inst); Pionyr; Sanofi
 
Seema Harichand-Herdt
No Relationships to Disclose
 
Glenn Sykes
No Relationships to Disclose
 
Naomi Haas
Consulting or Advisory Role - Eisai; Merck Sharp & Dohme
 
Michael Carducci
Honoraria - Remedica
Consulting or Advisory Role - Acrivon Therapeutics; AstraZeneca; Pfizer; Sanofi
Research Funding - Arcus Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); pfizer (Inst)
 
Raquibul Hannan
No Relationships to Disclose